Aardvark Therapeutics (AARD) Other financing activities (2024 - 2025)
Aardvark Therapeutics (AARD) reported Other financing activities of -$91.1 million for Q4 2025, down 8994.04% on a YoY basis from $1.0 million in Q4 2024, and down 200.12% sequentially from $91.0 million in Q2 2025.
Aardvark Therapeutics (AARD) Other financing activities (2024 - 2025) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Other financing activities data on file, last reported at -$91.1 million in Q4 2025.
- For the quarter ending Q4 2025, Other financing activities fell 8994.04% year-over-year to -$91.1 million; the trailing twelve-month figure through Mar 2026 stood at -$110000.0 (down 108.44% YoY), and the FY2024 full-year result was $1.2 million, changed N/A from the prior year.
- Other financing activities eased to -$91.1 million in Q4 2025, from $91.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $91.0 million in Q2 2025 to a low of -$91.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -91.08 Mn |
| Dec 31, 2025 | -91.08 Mn |
| Jun 30, 2025 | 90.97 Mn |
| Jun 30, 2025 | 90.97 Mn |
| Mar 31, 2025 | 110,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |